Custom peptide synthesis: difference between revisions
Diff·revision 7 → 8·22:50, 5 Jan 2025
Difference between revision 7 and revision 8 of Custom peptide synthesis. 5 lines changed; the page grew by 524 bytes.
| Revision 7 — 12:07, 20 Dec 2024 NPOV_Nadia (talk) state that overlay gas is used and name it 2,690 bytes ±0 | Revision 8 — 22:50, 5 Jan 2025 FreightFenna (talk) give the closure integrity test by name 3,214 bytes +524 | ||
|---|---|---|---|
| 26 | Sequence ambiguity is the failure with the largest consequence. One-letter and three-letter codes, D-residue conventions, and non-standard abbreviations for modified residues all vary between houses, and a sequence should be unambiguous on its face. See [[Peptide]]. | 26 | Sequence ambiguity is the failure with the largest consequence. One-letter and three-letter codes, D-residue conventions, and non-standard abbreviations for modified residues all vary between houses, and a sequence should be unambiguous on its face. See [[Peptide]]. |
| 27 | 27 | ||
| + | 28 | == What a quotation reveals == | |
| + | 29 | A quotation that names a delivery date, a purity grade and a determination set is a more informative document than one giving only a price. It says the supplier has assessed the sequence rather than applied a per-residue rate.{{r|behrendt2016}} | |
| + | 30 | ||
| + | 31 | Declining to quote is also informative and is not a negative signal. Some sequences are genuinely difficult, some require capability a given house does not have, and a house that declines rather than accepting and failing is behaving reasonably. | |
| + | 32 | ||
| 28 | == References == | 33 | == References == |
| 29 | {{reflist}} | 34 | {{reflist}} |